Million-Year-Old Weed Enzymes REVIVED

(LibertystarTribune.com) – Scientists have resurrected ancient cannabis enzymes, unlocking efficient biotech production of THC, CBD, and rare cannabinoids—potentially slashing costs in the booming medical market under President Trump’s pro-innovation agenda.

Story Highlights

Wageningen University researchers used ancestral sequence reconstruction to revive million-year-old cannabis enzymes more versatile than modern ones.
These “promiscuous” enzymes convert precursor CBGA into multiple cannabinoids like THC, CBD, and anti-inflammatory CBC in microbes like yeast.
Ancient versions prove robust, flexible, and easier to produce, bypassing costly plant cultivation for scalable drug manufacturing.
Study published December 26, 2026, in Plant Biotechnology Journal, offering tools for innovative medicines without government overreach.

Breakthrough in Enzyme Resurrection

Researchers at Wageningen University & Research in the Netherlands reconstructed three ancient cannabinoid oxidocyclase enzymes from cannabis ancestors millions of years old. Lead scientist Robin van Velzen’s team applied ancestral sequence reconstruction, analyzing modern plant DNA to infer and synthesize extinct proteins. These enzymes metabolize cannabigerolic acid into tetrahydrocannabinolic acid, cannabidiolic acid, and cannabichromenic acid. Unlike specialized modern enzymes post-gene duplication, ancestral forms handle multiple products simultaneously. This first experimental evidence traces CBGA metabolism to a recent cannabis ancestor, distinct from related plants like rhododendrons.

Advantages Over Modern Enzymes

Ancient enzymes demonstrate superior robustness and flexibility, producing THC, CBD, and CBC from CBGA more efficiently than today’s versions. The WUR team expressed them successfully in yeast, overcoming challenges with modern enzymes that resist heterologous production. Co-lead Cloé Villard and colleagues engineered hybrid enzymes, pinpointing mutations that refined specialization over evolution. Van Velzen stated these “unfinished” enzymes offer attractive starting points for biotechnology and pharmaceuticals. This approach supports sustainable drug development without relying on large-scale cannabis cultivation.

Publication in Plant Biotechnology Journal on December 26, 2026, followed lab validation around 2025-2026. Media outlets like New Atlas and ScienceAlert covered the findings promptly. No commercialization reported yet, but paths open for breeding CBC-rich varieties and microbial factories. This aligns with market-driven innovation, reducing costs in the $20 billion cannabis sector.

Biotech and Medical Implications

Short-term gains include faster, cheaper synthesis of rare cannabinoids like CBC for inflammation and pain relief, enabling research independent of plant harvests. Long-term, engineered plants and microbes could revolutionize cannabinoid therapeutics. Patients stand to benefit from evidence-based medicines, while pharma firms access efficient tools. WUR’s focus on plant biotech underscores evolutionary insights fueling practical advances. Under President Trump’s deregulatory stance, such private-sector breakthroughs promise American leadership in synthetic biology without taxpayer-funded overreach.

Conservative Perspective on Progress

This innovation exemplifies free-market science triumphing over bureaucratic hurdles. Past leftist policies stifled biotech with excessive regulations and globalist trade dependencies; now, Trump’s America prioritizes innovation for real medical solutions. Resurrected enzymes cut reliance on imported cannabis, bolstering domestic industry and jobs. Common sense dictates harnessing nature’s designs efficiently, protecting family health without promoting recreational excess or government control. Uniform expert acclaim reinforces the study’s credibility, with no contradictions noted.